
|Videos|July 13, 2015
The Role of Cholesterol-Lowering PCSK9 Inhibitors
Karen J. McConnell, Pharm.D., FCCP, BCPS, talks about the role that products like PCSK9 will play in the future.
Advertisement
Karen J. McConnell, Pharm.D., FCCP, BCPS, clinical pharmacy specialist in cardiology at the Kaiser Permanente of Colorado and associate professor at the Skaggs School of Pharmacy (University of Colorado) talks about the role that products like PCSK9 will play in the future.
This video was recorded at APhA’s Annual Meeting and Exposition in March 2015.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































